Artwork

Karen Jagoda에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 Karen Jagoda 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.
Player FM -팟 캐스트 앱
Player FM 앱으로 오프라인으로 전환하세요!

Developing Psychedelic Therapy for Rapid Improvement of Postpartum Depression with Greg Mayes Reunion Neuroscience

19:34
 
공유
 

Manage episode 455972428 series 99915
Karen Jagoda에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 Karen Jagoda 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.

Greg Mayes, President and CEO of Reunion Neuroscience, is developing a psychedelic therapy for the treatment of postpartum depression. This serious acute, non-chronic mental health condition affects an estimated 20% of women after giving birth. A phase two trial is underway to evaluate how RE-104, a rapid-acting psilocybin-like novel molecule, can help women with moderate to severe postpartum depression get faster relief compared to existing treatments.

Greg explains, "The course of our psychedelic administration is significant because we believe it can be shorter in time period than other psilocybin-like treatments. In our case, we were able to establish it as 3.7 hours. Because it's a psychedelic and it is for an acute and non-chronic indication, we believe that women who take our product will see a rapid uptake and potentially day of administration benefit of the psychedelic therapy. Our phase two study is called the RECONNECT study because it's named for women reconnecting with themselves, their families, their children, and the world around them."

"Postpartum depression is considered to be a subset depressive of major depressive disorder, major depressive order that's not put into remission after two treatments becomes treatment-resistant depression. There's also generalized anxiety disorder. We believe that RE104 and our lead product have a lot of legs to potentially go in this area. But as the CEO of the company, we want to stay focused. We know what we need to do first and foremost is we need to get our RECONNECT phase two proof of concept study and women with moderate to severe postpartum depression recruited. And we need to show that we can work there. Once we show that, we'll pivot to other indications. One is adjustment disorder in patients with cancer and with other major medical illnesses like Parkinson's disease, ALS, MS, or pulmonary fibrosis."

#ReunionNeuro #PostPartumDepression #PPD #Psychedelics #Mothers #MentalHealth #Depression #RECONNECTStudy

reunionneuro.com

PPDReconnectstudy.com

Download the transcript here

  continue reading

2011 에피소드

Artwork
icon공유
 
Manage episode 455972428 series 99915
Karen Jagoda에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 Karen Jagoda 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.

Greg Mayes, President and CEO of Reunion Neuroscience, is developing a psychedelic therapy for the treatment of postpartum depression. This serious acute, non-chronic mental health condition affects an estimated 20% of women after giving birth. A phase two trial is underway to evaluate how RE-104, a rapid-acting psilocybin-like novel molecule, can help women with moderate to severe postpartum depression get faster relief compared to existing treatments.

Greg explains, "The course of our psychedelic administration is significant because we believe it can be shorter in time period than other psilocybin-like treatments. In our case, we were able to establish it as 3.7 hours. Because it's a psychedelic and it is for an acute and non-chronic indication, we believe that women who take our product will see a rapid uptake and potentially day of administration benefit of the psychedelic therapy. Our phase two study is called the RECONNECT study because it's named for women reconnecting with themselves, their families, their children, and the world around them."

"Postpartum depression is considered to be a subset depressive of major depressive disorder, major depressive order that's not put into remission after two treatments becomes treatment-resistant depression. There's also generalized anxiety disorder. We believe that RE104 and our lead product have a lot of legs to potentially go in this area. But as the CEO of the company, we want to stay focused. We know what we need to do first and foremost is we need to get our RECONNECT phase two proof of concept study and women with moderate to severe postpartum depression recruited. And we need to show that we can work there. Once we show that, we'll pivot to other indications. One is adjustment disorder in patients with cancer and with other major medical illnesses like Parkinson's disease, ALS, MS, or pulmonary fibrosis."

#ReunionNeuro #PostPartumDepression #PPD #Psychedelics #Mothers #MentalHealth #Depression #RECONNECTStudy

reunionneuro.com

PPDReconnectstudy.com

Download the transcript here

  continue reading

2011 에피소드

모든 에피소드

×
 
Loading …

플레이어 FM에 오신것을 환영합니다!

플레이어 FM은 웹에서 고품질 팟캐스트를 검색하여 지금 바로 즐길 수 있도록 합니다. 최고의 팟캐스트 앱이며 Android, iPhone 및 웹에서도 작동합니다. 장치 간 구독 동기화를 위해 가입하세요.

 

빠른 참조 가이드